Last reviewed · How we verify
Placebo Drug
Placebo produces no pharmacological effect and works through psychological expectation and the placebo effect.
Placebo Drug, marketed by KK Women's and Children's Hospital, holds a niche position in the healthcare market with limited specific indications. The key composition patent is set to expire in 2028, which may provide some protection against generics in the interim. However, the lack of detailed revenue data and clear competitive positioning poses a significant risk to its market sustainability.
At a glance
| Generic name | Placebo Drug |
|---|---|
| Also known as | Control drug, Medication, treatment group, CAPOX, FOLFOX |
| Sponsor | KK Women's and Children's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance or sham treatment that contains no active pharmaceutical ingredient. Its therapeutic benefit, when observed, arises from patient expectation, conditioning, and psychological mechanisms rather than direct molecular action. Placebo is commonly used as a control in clinical trials to establish the efficacy of active drugs.
Approved indications
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Effect of Kinesio Taping Application in Addition to Pilates Exercises on Core Muscle Thickness, Cognition and Mental Fatigue in Individuals With Non-specific Low Back Pain (NA)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH (PHASE1, PHASE2)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |